Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw: A longitudinal cohort study

Prakash Varadarajan, Juan J. Toro, Shuko Lee, Deanna Schneider, Bonita Neumon, Brenda Frye, Robert M. Craig, David J. Haile, César O. Freytes

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose There is no information regarding the toxicity associated with autologous hematopoietic progenitor cell transplantation (AHPCT) in patients with multiple myeloma (MM) who have bisphosphonate-induced osteonecrosis of the jaw (ONJ). There is also limited information regarding long-term outcome of these patients. Methods In this retrospective cohort study, we compared the toxicity after AHPCT in MM patients with and without ONJ. We also analyzed the response rate and overall survival of this population of patients. Results During the study period, 176 patients underwent AHPCT at our institution for MM. Ten patients with ONJ prior to AHPCT were matched to 40 control patients without ONJ. The incidence and severity of transplantationassociated toxicities were similar in both groups, including mucositis, 50 % in patients with ONJ vs. 68 % in controls (p=0.889) and febrile days, median 1 vs. 3 days, respectively (p=0.524). Myeloid engraftment and hospital length of stay were also similar between patients with ONJ and controls. There were significantly more complete remissions in patients with ONJ than in control patients (45 % vs. 15 %, p=0.0336), but survival between the groups was not significantly different (log-rank p=0.0818). Conclusions We conclude that the incidence and severity of transplantation-associated toxicities are similar in MM patients with and without ONJ. Long-term survival was also similar between both groups.

Original languageEnglish (US)
Pages (from-to)2969-2975
Number of pages7
JournalSupportive Care in Cancer
Volume20
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Cell Transplantation
Hematopoietic Stem Cells
Multiple Myeloma
Longitudinal Studies
Cohort Studies
Osteonecrosis
Jaw
Length of Stay
Mucositis
Survival
Incidence

Keywords

  • Autologous hematopoietic progenitor cell transplantation
  • Multiple myeloma
  • Osteonecrosis of the jaw

ASJC Scopus subject areas

  • Oncology

Cite this

Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw : A longitudinal cohort study. / Varadarajan, Prakash; Toro, Juan J.; Lee, Shuko; Schneider, Deanna; Neumon, Bonita; Frye, Brenda; Craig, Robert M.; Haile, David J.; Freytes, César O.

In: Supportive Care in Cancer, Vol. 20, No. 11, 11.2012, p. 2969-2975.

Research output: Contribution to journalArticle

Varadarajan, Prakash ; Toro, Juan J. ; Lee, Shuko ; Schneider, Deanna ; Neumon, Bonita ; Frye, Brenda ; Craig, Robert M. ; Haile, David J. ; Freytes, César O. / Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw : A longitudinal cohort study. In: Supportive Care in Cancer. 2012 ; Vol. 20, No. 11. pp. 2969-2975.
@article{72c03e66b21445508667a28315e60dba,
title = "Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw: A longitudinal cohort study",
abstract = "Purpose There is no information regarding the toxicity associated with autologous hematopoietic progenitor cell transplantation (AHPCT) in patients with multiple myeloma (MM) who have bisphosphonate-induced osteonecrosis of the jaw (ONJ). There is also limited information regarding long-term outcome of these patients. Methods In this retrospective cohort study, we compared the toxicity after AHPCT in MM patients with and without ONJ. We also analyzed the response rate and overall survival of this population of patients. Results During the study period, 176 patients underwent AHPCT at our institution for MM. Ten patients with ONJ prior to AHPCT were matched to 40 control patients without ONJ. The incidence and severity of transplantationassociated toxicities were similar in both groups, including mucositis, 50 {\%} in patients with ONJ vs. 68 {\%} in controls (p=0.889) and febrile days, median 1 vs. 3 days, respectively (p=0.524). Myeloid engraftment and hospital length of stay were also similar between patients with ONJ and controls. There were significantly more complete remissions in patients with ONJ than in control patients (45 {\%} vs. 15 {\%}, p=0.0336), but survival between the groups was not significantly different (log-rank p=0.0818). Conclusions We conclude that the incidence and severity of transplantation-associated toxicities are similar in MM patients with and without ONJ. Long-term survival was also similar between both groups.",
keywords = "Autologous hematopoietic progenitor cell transplantation, Multiple myeloma, Osteonecrosis of the jaw",
author = "Prakash Varadarajan and Toro, {Juan J.} and Shuko Lee and Deanna Schneider and Bonita Neumon and Brenda Frye and Craig, {Robert M.} and Haile, {David J.} and Freytes, {C{\'e}sar O.}",
year = "2012",
month = "11",
doi = "10.1007/s00520-012-1429-4",
language = "English (US)",
volume = "20",
pages = "2969--2975",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Hematopoietic progenitor cell transplantation toxicities in multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw

T2 - A longitudinal cohort study

AU - Varadarajan, Prakash

AU - Toro, Juan J.

AU - Lee, Shuko

AU - Schneider, Deanna

AU - Neumon, Bonita

AU - Frye, Brenda

AU - Craig, Robert M.

AU - Haile, David J.

AU - Freytes, César O.

PY - 2012/11

Y1 - 2012/11

N2 - Purpose There is no information regarding the toxicity associated with autologous hematopoietic progenitor cell transplantation (AHPCT) in patients with multiple myeloma (MM) who have bisphosphonate-induced osteonecrosis of the jaw (ONJ). There is also limited information regarding long-term outcome of these patients. Methods In this retrospective cohort study, we compared the toxicity after AHPCT in MM patients with and without ONJ. We also analyzed the response rate and overall survival of this population of patients. Results During the study period, 176 patients underwent AHPCT at our institution for MM. Ten patients with ONJ prior to AHPCT were matched to 40 control patients without ONJ. The incidence and severity of transplantationassociated toxicities were similar in both groups, including mucositis, 50 % in patients with ONJ vs. 68 % in controls (p=0.889) and febrile days, median 1 vs. 3 days, respectively (p=0.524). Myeloid engraftment and hospital length of stay were also similar between patients with ONJ and controls. There were significantly more complete remissions in patients with ONJ than in control patients (45 % vs. 15 %, p=0.0336), but survival between the groups was not significantly different (log-rank p=0.0818). Conclusions We conclude that the incidence and severity of transplantation-associated toxicities are similar in MM patients with and without ONJ. Long-term survival was also similar between both groups.

AB - Purpose There is no information regarding the toxicity associated with autologous hematopoietic progenitor cell transplantation (AHPCT) in patients with multiple myeloma (MM) who have bisphosphonate-induced osteonecrosis of the jaw (ONJ). There is also limited information regarding long-term outcome of these patients. Methods In this retrospective cohort study, we compared the toxicity after AHPCT in MM patients with and without ONJ. We also analyzed the response rate and overall survival of this population of patients. Results During the study period, 176 patients underwent AHPCT at our institution for MM. Ten patients with ONJ prior to AHPCT were matched to 40 control patients without ONJ. The incidence and severity of transplantationassociated toxicities were similar in both groups, including mucositis, 50 % in patients with ONJ vs. 68 % in controls (p=0.889) and febrile days, median 1 vs. 3 days, respectively (p=0.524). Myeloid engraftment and hospital length of stay were also similar between patients with ONJ and controls. There were significantly more complete remissions in patients with ONJ than in control patients (45 % vs. 15 %, p=0.0336), but survival between the groups was not significantly different (log-rank p=0.0818). Conclusions We conclude that the incidence and severity of transplantation-associated toxicities are similar in MM patients with and without ONJ. Long-term survival was also similar between both groups.

KW - Autologous hematopoietic progenitor cell transplantation

KW - Multiple myeloma

KW - Osteonecrosis of the jaw

UR - http://www.scopus.com/inward/record.url?scp=84868458091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868458091&partnerID=8YFLogxK

U2 - 10.1007/s00520-012-1429-4

DO - 10.1007/s00520-012-1429-4

M3 - Article

C2 - 22418599

AN - SCOPUS:84868458091

VL - 20

SP - 2969

EP - 2975

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 11

ER -